Clinical Trial

Intratumoral Injection of Autologous CD1c (BDCA-1)+ MyDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab

Study acronym: myDAvIpNi
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 20, 2025 (before its estimated December 24, 2025 completion). Its status may not reflect the trial's current state.
Summary
This phase II trial aims at investigating the role and effect of autologous CD1c (BDCA-1)+ myeloid dendritic cells in combination with intratumoral injection of the CTLA-4 blocking monoclonal antibody (mAb) ipilimumab and the immunoligand AS01B compared to a combinatorial immunotherapy regimen using intratumoral injection of the CTLA-4 blocking monoclonal antibody (mAb) ipilimumab and the immunoligand AS01B. Concomitantly, nivolumab (a PD-1 blocking mAb) will be administered intravenously in both arms.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-10-12; most recent amendment 2025-01-17.
Status change: Completed → Recruiting 2025-01-17
Status change: Recruiting → Completed 2020-12-28
Trial Details
NCT Number NCT03707808
Lead Sponsor Universitair Ziekenhuis Brussel
Conditions Solid Tumor, Metastases to Soft Tissue
Enrollment 18 participants
Start Date 2018-01-29
Primary Completion 2025-12-24 (estimated)
Study Completion 2025-12-24 (estimated)
Updated on ClinicalTrials.gov 2025-01-20